OptiNose

Paratek Pharmaceuticals Acquires Optinose for $330 Million to Expand XHANCE Access in Chronic Rhinosinusitis Market

- Paratek Pharmaceuticals announced the acquisition of Optinose for up to $330 million, gaining access to XHANCE, the first and only approved treatment for chronic rhinosinusitis with or without nasal polyps. - The deal includes $9 per share upfront plus up to $5 per share in contingent value rights tied to XHANCE achieving net sales milestones of $150 million by 2028 and $225 million by 2029. - XHANCE's recent label expansion in 2024 increased its addressable market approximately 10-fold to include chronic rhinosinusitis without nasal polyps, representing a market of approximately 10 million patients. - Paratek plans to leverage its expanded primary care sales force to accelerate XHANCE adoption beyond ENT and allergy specialists to primary care providers who treat the majority of chronic rhinosinusitis patients.